Janux Therapeutics has initiated a Phase I clinical trial evaluating JANX014 for metastatic castration-resistant prostate cancer (mCRPC). The trial will assess the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy of the double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) in adults with mCRPC. The company is aiming to expand its portfolio of PSMA therapies to address various prostate cancer treatment settings and immune engagement mechanisms. Initial clinical data from JANx007 showed no Grade 3 cytokine release syndrome at clinically relevant dose levels, which has influenced the development of Janux's prostate cancer candidates.